Relapsed aggressive lymphoma: Can we optimize the therapy
EHA Library. Salles G. 06/14/17; 185059
Topic: 3Aa B lymphoblastic leukemia/lymphoma
Prof. Gilles Salles
Contributions
Contributions
Learning Objectives
Simon Rule - Chair Introduction
Our understanding of the molecular pathogenesis of the various types of aggressive lymphoma has increased markedly over recent years. The use of gene expression profiling helps define the different molecular pathways that the various disease sub-types are dependent upon. The importance of this with respect to prognostic and potential therapeutic implications has been recognised within the revised 2016 WHO classification and with the advent of multiple novel targeted agents this offers a real opportunity for new treatment approaches. Currently R-CHOP remains very much the standard of care for the commonest aggressive lymphomas, despite recent attempts to improve on this. The challenge remains in delivering effective curative therapy to older patients and those with co-morbidities. Part of the answer to this is in effectively assessing the physical health of the patient in a structured way in order to define the appropriate intensity of therapy that the patient can receive.
This session will provide insights into the management of aggressive NHL in the elderly as well as patients with relapsed disease and in addition will explore the new pathological basis of these diseases and how this might help in the development of new and improved approaches.
Learning Objectives of the manuscript
After viewing this presentation the participant will be able to:
- To better understand the molecular pathogenesis of aggressive NHL.
- To review the approach to the management of aggressive NHL in the elderly patient.
- To review the current approach to managing relapsed aggressive NHL and the potential new emerging therapies.
Learning Objectives of the presentation
After viewing this presentation the participant will be able to:
- Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
- Describe the different developments of innovative approaches in R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.
Our understanding of the molecular pathogenesis of the various types of aggressive lymphoma has increased markedly over recent years. The use of gene expression profiling helps define the different molecular pathways that the various disease sub-types are dependent upon. The importance of this with respect to prognostic and potential therapeutic implications has been recognised within the revised 2016 WHO classification and with the advent of multiple novel targeted agents this offers a real opportunity for new treatment approaches. Currently R-CHOP remains very much the standard of care for the commonest aggressive lymphomas, despite recent attempts to improve on this. The challenge remains in delivering effective curative therapy to older patients and those with co-morbidities. Part of the answer to this is in effectively assessing the physical health of the patient in a structured way in order to define the appropriate intensity of therapy that the patient can receive.
This session will provide insights into the management of aggressive NHL in the elderly as well as patients with relapsed disease and in addition will explore the new pathological basis of these diseases and how this might help in the development of new and improved approaches.
Learning Objectives of the manuscript
After viewing this presentation the participant will be able to:
- To better understand the molecular pathogenesis of aggressive NHL.
- To review the approach to the management of aggressive NHL in the elderly patient.
- To review the current approach to managing relapsed aggressive NHL and the potential new emerging therapies.
Learning Objectives of the presentation
After viewing this presentation the participant will be able to:
- Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
- Describe the different developments of innovative approaches in R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.
{{ help_message }}
{{filter}}